DK2718318T3 - Nye oxyntomodulinderivater og farmaceutiske sammensætninger til behandling af obesitas omfattende disse - Google Patents
Nye oxyntomodulinderivater og farmaceutiske sammensætninger til behandling af obesitas omfattende disse Download PDFInfo
- Publication number
- DK2718318T3 DK2718318T3 DK12797363.4T DK12797363T DK2718318T3 DK 2718318 T3 DK2718318 T3 DK 2718318T3 DK 12797363 T DK12797363 T DK 12797363T DK 2718318 T3 DK2718318 T3 DK 2718318T3
- Authority
- DK
- Denmark
- Prior art keywords
- obesity
- oxyntomodulin
- glu
- peptide
- ser
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Cell Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (11)
1. Peptid omfattende aminosyresekvensen ifølge ethver af SEQ ID NO: 24, 25 eller 26.
2. Peptid ifølge krav 1, hvor aminosyresekvensen omfatter SEQ ID NO: 24.
3. Peptid ifølge krav 1, hvor aminosyrerne ved positionerne 12 og 16 eller 16 og 20 danner en ring.
4. Peptid ifølge krav 3, hvor aminosyresekvensen omfatter SEQ ID NO: 25.
5. Peptid ifølge krav 3, hvor aminosyresekvensen omfatter SEQ ID NO: 26.
6. Peptid ifølge ethvert af de foregående krav, hvor peptidet har anti-obesitas-virkninger.
7. Farmaceutisk sammensætning til forebyggelse eller behandling af obesitas, omfattende peptidet ifølge ethvert af kravene 1 til 6 som en aktiv ingrediens.
8. Farmaceutisk sammensætning ifølge krav 7, som yderligere omfatter et farmaceutisk acceptabelt bærestof.
9. Farmaceutisk sammensætning ifølge krav 7 eller 8, hvor sammensætningen indgives alene eller i kombination eller samtidigt med andre farmaceutiske formuleringer, som har profylaktiske eller terapeutiske virkninger på obesitas.
10. Farmaceutisk sammensætning ifølge krav 10, hvor den farmaceutiske formulering, som har profylaktiske eller terapeutiske virkninger på obesitas er en GLP-1-receptor-agonist, en leptin-receptoragonist, en DPP-IV-inhibitor, en Y5-receptorantagonist, en melanin-koncentrerende hormon (MCH) receptorantagonist, en Y2/3-receptoragonist, en MC3/4-receptoragonist, en gastrisk/pankreatisk lipaseinhibitor, en 5HT2c-agonist, en 33A-receptoragonist, en amylin-receptoragonist, en ghrelinantagonist eller en ghrelin-receptorantagonist.
11. Peptid ifølge ethvert af kravene 1 til 6 eller en sammensætning ifølge ethvert af kravene 7 til 10 til anvendelse ved forebyggelse eller behandling af obesitas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20110056472 | 2011-06-10 | ||
| PCT/KR2012/004494 WO2012169798A2 (en) | 2011-06-10 | 2012-06-07 | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2718318T3 true DK2718318T3 (da) | 2018-11-05 |
Family
ID=47296599
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12797363.4T DK2718318T3 (da) | 2011-06-10 | 2012-06-07 | Nye oxyntomodulinderivater og farmaceutiske sammensætninger til behandling af obesitas omfattende disse |
| DK18177993.5T DK3434687T3 (da) | 2011-06-10 | 2012-06-07 | Hidtil ukendte oxyntomodulinderivater og farmaceutisk præparat til behandling af fedme omfattende samme |
| DK21161174.4T DK3878859T3 (da) | 2011-06-10 | 2012-06-07 | Hidtil ukendte oxyntomodulinderivater og farmaceutisk præparat til behandling af fedme omfattende disse |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18177993.5T DK3434687T3 (da) | 2011-06-10 | 2012-06-07 | Hidtil ukendte oxyntomodulinderivater og farmaceutisk præparat til behandling af fedme omfattende samme |
| DK21161174.4T DK3878859T3 (da) | 2011-06-10 | 2012-06-07 | Hidtil ukendte oxyntomodulinderivater og farmaceutisk præparat til behandling af fedme omfattende disse |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US9527898B2 (da) |
| EP (3) | EP3878859B1 (da) |
| JP (5) | JP6014127B2 (da) |
| KR (2) | KR101502299B1 (da) |
| CN (1) | CN103732618B (da) |
| AR (1) | AR086866A1 (da) |
| AU (4) | AU2012267398B2 (da) |
| BR (2) | BR112013031794B1 (da) |
| CA (2) | CA3064214C (da) |
| CL (1) | CL2013003547A1 (da) |
| CY (1) | CY1120781T1 (da) |
| DK (3) | DK2718318T3 (da) |
| ES (3) | ES2968043T3 (da) |
| HR (1) | HRP20181591T1 (da) |
| HU (1) | HUE040307T2 (da) |
| IL (3) | IL245557B (da) |
| LT (1) | LT2718318T (da) |
| MX (2) | MX350708B (da) |
| MY (1) | MY169309A (da) |
| PE (3) | PE20181299A1 (da) |
| PL (1) | PL2718318T3 (da) |
| PT (1) | PT2718318T (da) |
| RS (1) | RS57711B1 (da) |
| RU (2) | RU2612906C2 (da) |
| SG (2) | SG10201604564XA (da) |
| SI (1) | SI2718318T1 (da) |
| TW (2) | TWI619724B (da) |
| UA (2) | UA126465C2 (da) |
| WO (1) | WO2012169798A2 (da) |
| ZA (1) | ZA201309054B (da) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101382593B1 (ko) * | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
| DK2718318T3 (da) | 2011-06-10 | 2018-11-05 | Hanmi Science Co Ltd | Nye oxyntomodulinderivater og farmaceutiske sammensætninger til behandling af obesitas omfattende disse |
| WO2012173422A1 (en) * | 2011-06-17 | 2012-12-20 | Hanmi Science Co., Ltd. | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
| BR112014006684A2 (pt) | 2011-09-23 | 2017-03-28 | Novo Nordisk As | análogos de glucagon |
| KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
| AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| KR101993393B1 (ko) * | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| EA034499B1 (ru) | 2012-11-06 | 2020-02-13 | Ханми Фарм. Ко., Лтд. | Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина |
| KR20150096433A (ko) | 2012-12-21 | 2015-08-24 | 사노피 | 이중 glp1/gip 또는 삼중 glp1/gip/글루카곤 효능제 |
| BR112015025464A2 (pt) | 2013-04-18 | 2017-10-10 | Novo Nordisk As | coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico |
| AR096890A1 (es) | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn |
| AR096891A1 (es) | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo |
| EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
| EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| AR098614A1 (es) * | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Compuesto para el tratamiento de hipoglicemia severa |
| AR098615A1 (es) * | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
| MA43289B1 (fr) | 2014-01-20 | 2019-12-31 | Hanmi Pharm Ind Co Ltd | Insuline à action prolongée et utilisation associée |
| AU2015242657B2 (en) | 2014-03-31 | 2020-05-21 | Hanmi Pharm. Co., Ltd. | Method for improving solubility of protein and peptide by using immunoglobulin Fc fragment linkage |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| AR100695A1 (es) | 2014-05-30 | 2016-10-26 | Hanmi Pharm Ind Co Ltd | Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón |
| US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
| KR20150140177A (ko) | 2014-06-05 | 2015-12-15 | 한미약품 주식회사 | 단백질 및 펩타이드의 면역원성을 감소시키는 방법 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| WO2016108586A1 (ko) * | 2014-12-30 | 2016-07-07 | 한미약품 주식회사 | 안정성이 증가된 글루카곤 유도체 |
| KR102418477B1 (ko) * | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| PE20240215A1 (es) * | 2015-06-30 | 2024-02-16 | Hanmi Pharmaceutical Co Ltd | Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
| TN2018000231A1 (en) | 2015-12-31 | 2019-10-04 | Hanmi Pharm Ind Co Ltd | Long-acting conjugate of triple glucagon/glp-1/gip receptor agonist |
| MX2018014016A (es) * | 2016-05-16 | 2019-08-01 | Intarcia Therapeutics Inc | Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos. |
| EP3479841A4 (en) * | 2016-06-29 | 2020-03-04 | Hanmi Pharm. Co., Ltd. | GLUCAGON DERIVATIVE, CONJUGATE THEREOF, COMPOSITION COMPRISING SAME, AND THERAPEUTIC USE THEREOF |
| WO2018056764A1 (ko) | 2016-09-23 | 2018-03-29 | 한미약품 주식회사 | 인슐린 수용체와의 결합력이 감소된, 인슐린 아날로그 및 이의 용도 |
| WO2018105988A1 (ko) | 2016-12-05 | 2018-06-14 | 한미약품 주식회사 | 면역반응이 약화된 결합체 |
| CN108299554B (zh) * | 2017-01-13 | 2021-05-25 | 博瑞生物医药（苏州）股份有限公司 | 胃泌酸调节素类似物 |
| JP2020506932A (ja) | 2017-02-03 | 2020-03-05 | ハンミ ファーマシューティカル カンパニー リミテッド | 持続性が増加した生理活性物質の結合体及びその用途 |
| CN106986924A (zh) * | 2017-03-23 | 2017-07-28 | 中国药科大学 | 胃泌酸调节素（oxm）类似物及其应用 |
| TWI798209B (zh) | 2017-03-23 | 2023-04-11 | 南韓商韓美藥品股份有限公司 | 對胰島素受體有降低親和性之胰島素類似物之接合物及其用途 |
| KR101990075B1 (ko) * | 2018-07-19 | 2019-06-18 | ㈜ 디앤디파마텍 | 폴리펩티드를 포함하는 비만 예방 또는 치료용 약학 조성물 |
| CN112912095A (zh) | 2018-07-19 | 2021-06-04 | D&D制药技术股份有限公司 | 包括多肽的药物组合物 |
| US11970523B2 (en) * | 2018-07-25 | 2024-04-30 | China Pharmaceutical University | Long-acting oxyntomodulin hybrid peptide, preparation method therefor, and application thereof |
| KR20200038878A (ko) * | 2018-10-04 | 2020-04-14 | 한미약품 주식회사 | 글루카곤 및 이를 포함하는 조합물의 치료학적 용도 |
| US20200262887A1 (en) | 2018-11-30 | 2020-08-20 | Opko Ireland Global Holdings, Ltd. | Oxyntomodulin peptide analog formulations |
| KR20240053545A (ko) * | 2022-10-14 | 2024-04-24 | 한미약품 주식회사 | 신규한 glp-1 수용체 길항제 및 이를 포함하는 선천성 고인슐린증 또는 저혈당증의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| WO1999044630A1 (fr) | 1998-03-06 | 1999-09-10 | Chugai Seiyaku Kabushiki Kaisha | Preparations exemptes de proteines |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| US7217845B2 (en) | 2002-11-25 | 2007-05-15 | Sun Bio, Inc. | Bifunctional polyethylene glycol derivatives |
| GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| EP1594530A4 (en) * | 2003-01-22 | 2006-10-11 | Human Genome Sciences Inc | HYBRID PROTEINS OF ALBUMIN |
| US7772188B2 (en) * | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2005035761A1 (en) | 2003-10-16 | 2005-04-21 | Compugen Ltd. | Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin |
| US20090238838A1 (en) | 2003-11-13 | 2009-09-24 | Hanmi Pharm. Ind. Co. Ltd. | Insulinotropic peptide conjugate using an immunoglobulin fc |
| KR101135244B1 (ko) | 2007-11-29 | 2012-04-24 | 한미사이언스 주식회사 | 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물 |
| US8263084B2 (en) | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
| ES2372495T3 (es) | 2003-11-13 | 2012-01-20 | Hanmi Holdings Co., Ltd | Método para la producción en masa de la región constante de inmunoglobulina. |
| JP5185624B2 (ja) | 2004-12-02 | 2013-04-17 | ドマンティス リミテッド | 血清アルブミンおよびｇｌｐ−１またはｐｙｙを標的とする二重特異性抗体 |
| BRPI0606992A2 (pt) * | 2005-02-11 | 2009-07-28 | Amylin Pharmaceuticals Inc | análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis |
| KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물 |
| GB0511986D0 (en) | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| KR101349808B1 (ko) * | 2005-06-13 | 2014-02-13 | 임페리얼 이노베이션스 리미티드 | 섭취행동에 관한 신규 화합물들 및 이들의 효능 |
| EP2330124B1 (en) | 2005-08-11 | 2015-02-25 | Amylin Pharmaceuticals, LLC | Hybrid polypeptides with selectable properties |
| CN101389648B (zh) * | 2006-02-22 | 2013-07-17 | 默沙东公司 | 肽胃泌酸调节素衍生物 |
| CA2654055A1 (en) | 2006-06-07 | 2007-12-21 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| GB0624868D0 (en) | 2006-12-13 | 2007-01-24 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| US20090098130A1 (en) | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| EP2111414B1 (en) * | 2007-02-15 | 2014-07-02 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| CN101730523A (zh) | 2007-07-10 | 2010-06-09 | 伊莱利利公司 | GLP-1-Fc融合蛋白质制剂 |
| KR20100058550A (ko) | 2007-09-11 | 2010-06-03 | 몬도바이오테크 래보래토리즈 아게 | 녹농균 감염 치료시 치료제로서의 밴드 ３ 단백질 （８２４－８２９） 및／또는 멜라닌세포－자극 호르몬 방출－저해 인자의 용도 |
| MX2010004298A (es) | 2007-10-30 | 2010-05-03 | Univ Indiana Res & Tech Corp | Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1. |
| WO2009099763A1 (en) | 2008-01-30 | 2009-08-13 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
| PA8830501A1 (es) * | 2008-06-17 | 2010-07-27 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
| MX2010012695A (es) | 2008-06-17 | 2011-03-15 | Univ Indiana Res & Tech Corp | Analogos de glucagon que exhiben solubilidad y estabilidad aumentadas en soluciones reguladoras de ph fisiologico. |
| WO2010013012A2 (en) | 2008-08-01 | 2010-02-04 | Lund University Bioscience Ab | Novel polypeptides and uses thereof |
| US20110171312A1 (en) | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Modified therapeutic peptides, methods of their preparation and use |
| EP2350118B1 (en) | 2008-09-19 | 2016-03-30 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
| BRPI0823379A2 (pt) | 2008-12-15 | 2015-07-14 | Zealand Pharma As | Análogos de glucagon |
| RU2550696C2 (ru) | 2008-12-19 | 2015-05-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Основанные на амидах пролекарства пептидов глюкагонового надсемейства |
| WO2010096052A1 (en) * | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| RU2495881C2 (ru) * | 2009-03-20 | 2013-10-20 | Ханми Холдингс Ко., Лтд. | Способ регулирования условий для сайт-специфического связывания полипептида и непептидильного полимера |
| MX347295B (es) | 2009-03-20 | 2017-04-20 | Amgen Inc | Inmunoglobulinas portadoras y usos de las mismas. |
| WO2010148089A1 (en) | 2009-06-16 | 2010-12-23 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| JP6054742B2 (ja) | 2009-07-13 | 2016-12-27 | ジーランド ファーマ アクティーゼルスカブ | アシル化グルカゴン類似体 |
| WO2011056713A2 (en) | 2009-11-03 | 2011-05-12 | Amylin Pharmaceuticals, Inc. | Glp-1 receptor agonist compounds for obstructive sleep apnea |
| US20120269830A1 (en) | 2009-12-07 | 2012-10-25 | Lawrence Horowitz | Conjugates with improved pharmacokinetic properties |
| WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| JO2976B1 (en) | 2009-12-22 | 2016-03-15 | ايلي ليلي اند كومباني | Axentomodulin polypeptide |
| AR079344A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
| JP6054861B2 (ja) | 2010-03-26 | 2016-12-27 | ノヴォ ノルディスク アー／エス | 新規のグルカゴン類似体 |
| EP2568993A4 (en) | 2010-05-13 | 2014-02-19 | Univ Indiana Res & Tech Corp | GLUCAGON SUPERFAMILY PEPTIDES EXPRESSING G PROTEIN-COUPLED RECEPTOR ACTIVITY |
| CN103179979A (zh) | 2010-06-24 | 2013-06-26 | 印第安纳大学研究及科技有限公司 | 基于酰胺的胰高血糖素超家族肽前药 |
| KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
| CN101974077A (zh) | 2010-09-15 | 2011-02-16 | 南京瑞年天平医药科技有限公司 | 一种新颖的多肽化合物 |
| KR101303388B1 (ko) | 2010-10-26 | 2013-09-03 | 한미사이언스 주식회사 | 지속형 인터페론 알파 결합체의 액상 제제 |
| KR101767570B1 (ko) | 2010-10-26 | 2017-08-14 | 한미사이언스 주식회사 | 항 비만 펩타이드의 지속형 결합체 |
| CN102010473A (zh) | 2010-11-10 | 2011-04-13 | 曹鹏 | 重组胃泌酸调节素融合蛋白及其制备和应用 |
| WO2012088379A2 (en) | 2010-12-22 | 2012-06-28 | Marcadia Biotech, Inc. | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides |
| JP6118500B2 (ja) | 2011-02-28 | 2017-04-19 | ローム アンド ハース エレクトロニック マテリアルズ エルエルシーＲｏｈｍ ａｎｄ Ｈａａｓ Ｅｌｅｃｔｒｏｎｉｃ Ｍａｔｅｒｉａｌｓ ＬＬＣ | フォトレジスト組成物、およびフォトリソグラフィパターンを形成する方法 |
| KR101161526B1 (ko) | 2011-05-16 | 2012-07-02 | 숭실대학교산학협력단 | 연료전지용 촉매전극을 위한 코어/쉘 구조의 나노 지지체 및 그 제조방법 |
| DK2718318T3 (da) | 2011-06-10 | 2018-11-05 | Hanmi Science Co Ltd | Nye oxyntomodulinderivater og farmaceutiske sammensætninger til behandling af obesitas omfattende disse |
| WO2012173422A1 (en) | 2011-06-17 | 2012-12-20 | Hanmi Science Co., Ltd. | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
| RU2014101697A (ru) | 2011-06-22 | 2015-07-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Коагонисты рецепторов глюкагона/glp-1 |
| WO2013157002A1 (en) | 2012-04-19 | 2013-10-24 | Prolor Biotech Inc. | Long-acting oxyntomodulin variants and methods of producing same |
| AR091477A1 (es) | 2012-06-21 | 2015-02-04 | Univ Indiana Res & Tech Corp | Analogos de glucagon que presentan actividad de receptor de gip |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| EA034499B1 (ru) | 2012-11-06 | 2020-02-13 | Ханми Фарм. Ко., Лтд. | Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина |
| JP6137046B2 (ja) | 2014-05-09 | 2017-05-31 | 信越化学工業株式会社 | 単量体、高分子化合物、レジスト材料及びパターン形成方法 |
-
2012
- 2012-06-07 DK DK12797363.4T patent/DK2718318T3/da active
- 2012-06-07 BR BR112013031794-9A patent/BR112013031794B1/pt active IP Right Grant
- 2012-06-07 BR BR122020011001-5A patent/BR122020011001B1/pt active IP Right Grant
- 2012-06-07 EP EP21161174.4A patent/EP3878859B1/en active Active
- 2012-06-07 SI SI201231406T patent/SI2718318T1/sl unknown
- 2012-06-07 WO PCT/KR2012/004494 patent/WO2012169798A2/en active Application Filing
- 2012-06-07 ES ES21161174T patent/ES2968043T3/es active Active
- 2012-06-07 EP EP12797363.4A patent/EP2718318B1/en active Active
- 2012-06-07 JP JP2014514799A patent/JP6014127B2/ja active Active
- 2012-06-07 RU RU2013154066A patent/RU2612906C2/ru active
- 2012-06-07 EP EP18177993.5A patent/EP3434687B1/en active Active
- 2012-06-07 AU AU2012267398A patent/AU2012267398B2/en active Active
- 2012-06-07 DK DK18177993.5T patent/DK3434687T3/da active
- 2012-06-07 PE PE2018000633A patent/PE20181299A1/es unknown
- 2012-06-07 RS RS20181080A patent/RS57711B1/sr unknown
- 2012-06-07 MY MYPI2013004355A patent/MY169309A/en unknown
- 2012-06-07 US US14/124,969 patent/US9527898B2/en active Active
- 2012-06-07 PE PE2023001927A patent/PE20240686A1/es unknown
- 2012-06-07 SG SG10201604564XA patent/SG10201604564XA/en unknown
- 2012-06-07 MX MX2013014468A patent/MX350708B/es active IP Right Grant
- 2012-06-07 ES ES12797363.4T patent/ES2692187T3/es active Active
- 2012-06-07 DK DK21161174.4T patent/DK3878859T3/da active
- 2012-06-07 UA UAA201610384A patent/UA126465C2/uk unknown
- 2012-06-07 PE PE2013002789A patent/PE20140765A1/es active IP Right Grant
- 2012-06-07 PL PL12797363T patent/PL2718318T3/pl unknown
- 2012-06-07 CA CA3064214A patent/CA3064214C/en active Active
- 2012-06-07 CN CN201280038851.4A patent/CN103732618B/zh active Active
- 2012-06-07 AR ARP120102030A patent/AR086866A1/es active IP Right Grant
- 2012-06-07 RU RU2017105866A patent/RU2739209C2/ru active
- 2012-06-07 CA CA2838503A patent/CA2838503C/en active Active
- 2012-06-07 KR KR1020120061166A patent/KR101502299B1/ko active IP Right Grant
- 2012-06-07 SG SG2013089065A patent/SG195258A1/en unknown
- 2012-06-07 HU HUE12797363A patent/HUE040307T2/hu unknown
- 2012-06-07 UA UAA201314212A patent/UA114710C2/uk unknown
- 2012-06-07 PT PT12797363T patent/PT2718318T/pt unknown
- 2012-06-07 LT LTEP12797363.4T patent/LT2718318T/lt unknown
- 2012-06-07 ES ES18177993T patent/ES2875748T3/es active Active
- 2012-06-08 TW TW101120633A patent/TWI619724B/zh active
- 2012-06-08 TW TW106133132A patent/TWI674271B/zh active
-
2013
- 2013-12-03 ZA ZA2013/09054A patent/ZA201309054B/en unknown
- 2013-12-09 MX MX2022004041A patent/MX2022004041A/es unknown
- 2013-12-10 CL CL2013003547A patent/CL2013003547A1/es unknown
-
2014
- 2014-10-22 KR KR1020140143510A patent/KR101573636B1/ko active IP Right Grant
-
2015
- 2015-06-24 US US14/748,389 patent/US9522946B2/en active Active
-
2016
- 2016-05-09 IL IL245557A patent/IL245557B/en active IP Right Grant
- 2016-09-23 JP JP2016185142A patent/JP6312765B2/ja active Active
- 2016-10-06 US US15/286,708 patent/US9765131B2/en active Active
- 2016-12-14 AU AU2016273908A patent/AU2016273908B2/en active Active
-
2017
- 2017-08-11 US US15/675,274 patent/US10442848B2/en active Active
-
2018
- 2018-03-19 JP JP2018050587A patent/JP2018117629A/ja active Pending
- 2018-07-12 IL IL260582A patent/IL260582B/en active IP Right Grant
- 2018-08-06 AU AU2018213964A patent/AU2018213964B2/en active Active
- 2018-10-03 HR HRP20181591TT patent/HRP20181591T1/hr unknown
- 2018-10-23 CY CY181101088T patent/CY1120781T1/el unknown
-
2019
- 2019-05-17 JP JP2019093562A patent/JP6862493B2/ja active Active
- 2019-08-28 IL IL268984A patent/IL268984B/en active IP Right Grant
-
2020
- 2020-02-24 AU AU2020201322A patent/AU2020201322B2/en active Active
- 2020-07-27 JP JP2020126268A patent/JP7094327B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2718318T3 (da) | Nye oxyntomodulinderivater og farmaceutiske sammensætninger til behandling af obesitas omfattende disse | |
| NZ755534B2 (en) | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same | |
| NZ740049B2 (en) | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same | |
| NZ734808B2 (en) | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same | |
| NZ748012B2 (en) | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same | |
| NZ717174B2 (en) | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same | |
| NZ618810B2 (en) | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same | |
| NZ731342B2 (en) | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |